Table 4

Doses of rituximab stratified by response in patients with different autoimmune diseases

Mean (SD) dose, mg


Diagnosis

No

response

Partial

response

Complete response


Total

n = 39

1,990 (798)

n = 132

2,683 (1,408)

n = 122

2,528 (1,346)

Arthritis (non-RA)/ankylosing spondylitis/psoriatic arthritis

n = 1

2,000 (-)

n = 4

2,500 (1,000)

-

Autoimmune haemolytic anaemia

n = 1

2,320 (-)

n = 1

2,000 (-)

n = 1

2,380 (-)

Autoimmune thrombocytopenia

-

n = 5

2,248 (1,321)

n = 5

2,956 (641)

Glomerulonephritis

-

n = 6

1,625 (826)

n = 2

4,100 (2,970)

Cryoglobulinaemic vasculitis

-

n = 3

2,960 (1,154)

n = 1

2,000 (-)

Wegener's granulomatosis/microscopic polyangiitis

n = 4

2,193 (561)

n = 29

3,474 (1,642)

n = 22

2,586 (1,384)

Multiple sclerosis/neuromyelitis optica

n = 9

2,022 (570)

n = 31

2,678 (903)

n = 14

3,157 (1,992)

Myasthenia gravis

-

n = 2

2,500 (707)

n = 2

1,225 (1,662)

Pemphigus

n = 2

1,500 (707)

n = 13

1,770 (899)

n = 22

1,769 (1,352)

Sjögren's syndrome

-

n = 2

2,312 (441)

n = 2

3,000 (1,414)

Polydermatomyositis

n = 5

1,700 (447)

n = 6

3,900 (3,209)

n = 10

2,818 (1,003)

Systemic lupus erythematosus

n = 15

2,121 (1,099)

n = 27

2,440 (1,119)

n = 37

2,499 (926)

Vasculitis

n = 2

1,500 (707)

n = 3

2,200 (346)

n = 4

3,000 (1,155)


RA, rheumatoid arthritis; SD, standard deviation.

Tony et al. Arthritis Research & Therapy 2011 13:R75   doi:10.1186/ar3337

Open Data